Clinical Trials Directory

Trials / Completed

CompletedNCT07367555

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patients"

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
360 (actual)
Sponsor
Ariba Shafiq · Academic / Other
Sex
All
Age
30 Years – 70 Years
Healthy volunteers
Not accepted

Summary

Total of 360 participants were enrolled and prescribed oral 200 mg SGLT-2 tablet. All participants were followed-up for about three months. Body mass index was measured before and after three months and mean change in BMI was assessed.

Conditions

Interventions

TypeNameDescription
DRUGOral 100 gram Empagliflozin tablet along with diet plan and exerciseoral 100 gram Empagliflozin tablet along with diet plan and exercise
OTHERDiet plan and exerciseOnly Life style modification was advised. Changes in BMI were assessed.

Timeline

Start date
2024-10-01
Primary completion
2025-03-31
Completion
2025-03-31
First posted
2026-01-26
Last updated
2026-01-26

Locations

1 site across 1 country: Pakistan

Source: ClinicalTrials.gov record NCT07367555. Inclusion in this directory is not an endorsement.

Effect Of Sodium Glucose Co-Transporter-2 (SGLT-2) Inhibitors on Body Mass Index After 3 Months of Use in Diabetic Patie (NCT07367555) · Clinical Trials Directory